GW Pharmaceuticals plc (NASDAQ: GWPH) announced this morning that the company’s wholly owned subsidiary, Greenwich Biosciences, plans to raise $300 million dollars via the selling GW Pharma’s common shares on the NASDAQ Global Market.
The company is planning to offer the underwriters an additional 30-day option to purchase an additional $45 million of the company’s shares. Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, J.P. Morgan and Cowen and Company, LLC are acting as joint book-running managers for the offering.
GW Pharma recently had their cannabis derived CBD pharmaceutical drug, Epidiolex, approved by both the FDA and DEA to be sold and prescribed by licensed physicians. Epidiolex is an oral solution that is used for the reduction of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. The product is the first CBD based medicine approved by the United States government.
GW also commercialized the cannabinoid prescription drug, Sativex®, which is now approved for the treatment of multiple sclerosis in multiple countries outside the United States. GW Pharma is currently conducted Phase 3 trails within the U.S. to get it approved as well. The company’s stock is currently trading at $13.04 per share.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…